Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech announced that CEO Dr. Matt Coffey is taking a medical leave of absence, with Wayne Pisano stepping in as interim CEO. The company remains focused on advancing its cancer treatment, pelareorep, towards critical clinical trials in breast and pancreatic cancer. Notably, pelareorep has shown promise in early studies and has garnered Fast Track designation from the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
